Ultragenyx Pharmaceutical Inc. reported $717M of revenue over the trailing twelve months, +18% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $717M (to Q2 2026). Net income: −$586M, trailing twelve months to Q2 2026. Free cash flow: −$489M, trailing twelve months to Q2 2026. Operating margin: −80%, trailing twelve months to Q2 2026.

RAREUltragenyx Pharmaceutical Inc.

Healthcare

$15.49-45% 1Y

$15.49

$12.9052 weeks$36.54

RARE as reported

Ultragenyx Pharmaceutical Inc. reported $717M of revenue over the trailing twelve months, +18% on the year before. 9 reported series are charted on this page, each one as filed.

$717M

Revenue, trailing twelve months · to Q2 2026 · +18% against the twelve months before

Net income: −$586M
Net income · +10.0% year on year · trailing twelve months to Q2 2026
Free cash flow: −$489M
Free cash flow · +14% year on year · trailing twelve months to Q2 2026
Operating margin: −80%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for RARE, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$717M	+18%	Q2 2026
Net income	−$586M	+10.0%	Q2 2026
EPS	−$5.83	+5.6%	Q2 2026
Gross margin	97%	n/a	Q2 2019 · 28 quarters behind
Operating margin	−80%	n/a	Q2 2026
Net margin	−88%	n/a	Q2 2026
ROE	−1288%	n/a	Q2 2026
ROA	−45%	n/a	Q2 2026
Free cash flow	−$489M	+14%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.